2-(n-propylamino)thiazole | 78508-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(n-propylamino)thiazole
• 英文别名: N-propyl-1,3-thiazol-2-amine
• CAS: 78508-32-4
• 化学式: C₆H₁₀N₂S
• mdl: MFCD11119201
• 分子量: 142.225
• InChiKey: MQQNXHJDLKZGTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  bis(2,4,6-trichlorophenyl) n-propylmalonate 、 2-(n-propylamino)thiazole 反应 0.05h， 以45%的产率得到anhydro-6,8-di-n-propyl-5-hydroxy-7-oxothiazolo<3,2-a>pyrimidinium hydroxide
  参考文献：
  名称：

  Mesoionic xanthine analogs: antagonists of adenosine receptors

  摘要：

  A variety of mesoionic xanthines including mesoionic thiazolo[3,2-alpha]pyrimidines, benzothiazolopyrimidines, and 1,3,4-thiadiazolo[3,2-alpha]pyrimidines were antagonists of A1-adenosine receptors (inhibition of binding of [3H]-cyclohexyladenosine) and A2-adenosine receptors (inhibition of 2-chloroadenosine-elicited accumulations of cyclic AMP) in brain tissue. Most of the compounds were less potent than theophylline and none were remarkably selective for A1- or A2-adenosine receptors. However, members of the thiadiazolopyrimidine class of mesoionics exhibited very low or no activity as antagonists of A2-adenosine receptors while exhibiting activity only 2-4-fold lower than that of theophylline at A1-adenosine receptors. Unlike the case for theophylline, the presence of a phenyl substituent in the five-membered ring did not enhance the potency of a mesoionic thiadiazolopyrimidine. The nature of the substituents on the mesoionic ring did not appear to have marked effects on potency unlike the marked effect of the nature of 1,3-substituents on activity of nonmesoionic xanthines. The benzothiazolo[3,2-alpha]pyrimidines were the most potent antagonists, being nearly as potent as theophylline at A1-adenosine receptors and somewhat more potent than theophylline at A2-adenosine receptors.

  DOI：

  10.1021/jm00376a027
• 作为产物：
  描述：

  Thiazol-2-yl-(1-p-tolylsulfanyl-propyl)-amine 在 sodium tetrahydroborate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 1.7h， 以4.6 g的产率得到2-(n-propylamino)thiazole
  参考文献：
  名称：

  硼氢化钠将伯胺与醛和对硫甲酚的加合物还原。杂环和芳族氨基化合物的烷基化

  摘要：

  对硝基苯胺，2-氨基吡啶（1a），4-氨基吡啶（2a），2-氨基-4-甲基嘧啶（8a），2-氨基噻唑（10a）和2-氨基苯并咪唑（12a）与甲醛水溶液反应，对-通常在高收率下在乙醇或甲醇溶液中用硫代甲酚制得N-（对甲苯硫基甲基）衍生物[对应于通式（4; R 2 = H）]。当后一化合物在乙醇或1，2-二甲氧基乙烷溶液中与过量的硼氢化钠加热回流时，相应的甲氨基化合物[通式（5; R 2= H）]。通过其中的甲醛水溶液被替换，酌情无水乙醛，丙醛，苯甲醛或类似的两个步骤，p硝基苯胺转化成Ñ乙基p硝基苯胺，p -chloroaniline被转换成p氯代N-（正丙基）苯胺，（1a）分别转化为相应的乙基氨基和苄基氨基化合物（1c）和（1d），（10a）和（12a）转化为它们的2- N-（正丙基）衍生物（10c）和（12c）。

  DOI：

  10.1039/p19810001569

文献信息

• MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS
  申请人：Marsault Eric

  公开号：US20100093720A1

  公开（公告）日：2010-04-15

  The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

  本发明提供了与胃动素受体及其亚型、异构体和/或变体结合和/或是功能调节剂的构象定义明确的大环化合物。这些大环化合物至少具有足够的药理特性，可用作治疗一系列疾病指示的治疗药物。特别是，这些化合物对于治疗和预防以高胃动素血症和/或胃肠道高蠕动性为特征的疾病非常有用，包括但不限于腹泻、癌症治疗相关腹泻、癌症诱导腹泻、化疗诱导腹泻、放射性肠炎、放射性腹泻、压力诱导腹泻、慢性腹泻、艾滋病相关腹泻、C. difficile相关腹泻、旅行者腹泻、移植物宿主病引起的腹泻、其他类型的腹泻、消化不良、肠易激综合征、化疗诱导的恶心和呕吐（呕吐）以及术后恶心和呕吐和功能性胃肠道疾病。此外，这些化合物对于治疗以胃或肠道吸收不良为特征的疾病和疾病也具有用途，例如短肠综合征、乳糜泻和虚弱。这些化合物还可用于治疗胃肠道炎症性疾病和疾病，如炎症性肠病、溃疡性结肠炎、克罗恩病和胰腺炎。因此，本发明还提供了治疗此类疾病的方法和包括本发明化合物的药物组合物。
• [EN] AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAINDAZOLE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010036632A1

  公开（公告）日：2010-04-01

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  公开的是化合物的公式（I），用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫性疾病，如风湿性关节炎和多发性硬化症。还公开了制备方法和使用方法。
• [EN] VIRAL POLYMERASE INHIBITORS<br/>[FR] INHIBITEURS DE POLYMERASE VIRALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009018656A1

  公开（公告）日：2009-02-12

  Compound of Formula I: wherein, R2, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase

  化合物的化学式I：其中，R2、R5和R6如本文所定义，可用作乙型肝炎病毒NS5B聚合酶的抑制剂。
• [EN] ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS ANTIMICROBIENS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION DE CEUX-CI
  申请人：MELINTA THERAPEUTICS INC

  公开号：WO2016145417A1

  公开（公告）日：2016-09-15

  The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals.

  本公开涉及抗微生物化合物领域，以及制备和使用这些化合物的方法。这些化合物可用于治疗、预防、降低人类和动物微生物感染的风险，并延缓感染的发生。
• 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080176857A1

  公开（公告）日：2008-07-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药物可接受的盐，其中化合物具有公式I的结构：其中A1、A2、A3、A4、A5、A6、A7、A8、X4、X6、R2、R4、R5和R6如本发明详细描述中所定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。